Trial · NCT07146893
Feasibility Study for Repurposing RET Inhibitors
NCT07146893, Early phase 1, Not yet recruiting, University of Oklahoma
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Feasibility Study for Repurposing RET Inhibitors. Trials, record NCT07146893. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07146893
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Feasibility Study for Repurposing RET Inhibitors
- NCT number
- NCT07146893
- Status
- Not yet recruiting
- Phases
- Early phase 1
- Enrollment
- 7 participants, estimated
- Lead sponsor
- University of Oklahoma
- Conditions
- Cachexia-Anorexia Syndrome
- Interventions
- Selpercatinib, Strength Assessment
- First posted
- 2025-08-28
- Last updated
- 2026-01-15
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean (± SD) changes in body weight after 12 weeks | 12 weeks | At screening, patients will have their initial weight recorded. While on study, they will take selpercatinib orally twice daily, with weight assessments conducted every four weeks (Weeks 4, 8, and 12). Selpercatinib will be discontinued at Week 12, and at the 16-week post-treatment follow-up, patients will return to the clinic for a final weight assessment. |
| Primary | Mean (± SD) percentage of doses of selpercatinib taken on time by patient | 12 weeks | A pill diary will be provided to patients to record the time, date, and dose (40 mg or 80 mg) of selpercatinib before starting the study drug. |
| Secondary | Mean (± SD) changes in anorexic behaviors after 12 weeks | 12 weeks | Patients will be administered a Functional Assessment of Anorexia Cachexia- Anorexia Cachexia Subscale (FAACT-ACS) at baseline, and again at 12 weeks. The FAACT-ACS is designed to assess patient well-being and concerns using a Likert scale, where responses range from 0 to 4. A score of 0 indicates "Not at all," representing the lowest level of agreement or concern, while a score of 4 indicates "Very much," representing the highest level. |
| Secondary | Mean (± SD) changes in skeletal muscle while taking selpercatinib | 12 Weeks | Regular blood draws every 4 weeks while on selpercatinib will be taken with the goal of quantifying GDF-15 levels in each patient. Also a lumbar muscle assessment using a CT scan at baseline and again at 12 weeks to assess for muscle changes while taking selpercatinib. |
| Secondary | Mean (± SD) changes in Strength outcomes in patients taking selpercatinib | 12 weeks | A Hallux Strength Test will be conducted at baseline and repeated at 12 weeks (+/- 2 weeks), measuring grip strength, timed chair stands, leg press, and localized ultrasound of the quadriceps. |
| Secondary | Mean (± SD) changes in plasma GDF-15 while taking selpercatinib | 12 Weeks | Regular blood draws every 4 weeks while on selpercatinib will be taken with the goal of quantifying GDF-15 levels in each patient. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07146893
GET https://conductscience.org/api/trials/v1/NCT07146893/registered